Navigation Links
OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Date:12/4/2008

BOTHELL, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc (NASDAQ: OGXI) will participate on the 'Waging a Battle Against Cancer' panel at the RBC Capital Markets 2008 Healthcare Conference on Thursday, December 11 at 8:00 am ET at the Westin Times Square Hotel in New York. During the panel discussion, OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a brief overview of the company's oncology drug pipeline and its approach for addressing cancer treatment resistance.

A live webcast of the panel will be available on the Events section of the Investor Relations page of the company Web site at www.oncogenex.com. A replay of the webcast will be available for 30 days following the event.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Filippov (MIPT and Russian Quantum Center at Skolkovo) ... Republic, and the Institute of Physics in Bratislava, ... entanglement of particles passing through an amplifier and, ... Details are provided in an article published in ... preprint). , Quantum entangled particles are considered to ...
(Date:7/23/2014)... , July 23, 2014  AuraSense ... constructs as gene regulatory and immunotherapeutic agents, ... has joined AuraSense Therapeutics, executive leadership team ... Prior to joining AuraSense Therapeutics, ... Chief Financial Officer of Cellular Dynamics International ...
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2
... First prize of $10,000 in the G. Steven Burrill ... Energy Systems, Inc., represented by Shailesh Ghimire, a second-year ... with a PhD in food science. Virent Energy Systems ... products like rice hulls and whey. , ,In total, ...
... shares shot up 40% this morning after it announced that ... the company's pipeline, has been found to extend the lives ... week, new data and a regulatory decision buttressed the outlook ... news - people ) is developing with smaller ...
... Westchester Medical Center (WMC), Valhalla, New York, has selected Verisis ... of Analogic Corporation , for its new Cardiology Image ... installed at WMC's George E. Reed Heart Center , ... programs on the east coast. The system will also extend ...
Cached Biology Technology:Students Win Burrill Competition With Plan for Renewable Energy 2Genentech's Winning Streak 2Genentech's Winning Streak 3NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management 2
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
(Date:7/24/2014)... researchers led by the University of York has carried ... the Western Indian Ocean. , The results, reported ... a revolution in the management of marine protected areas, ... 11,000 km in the region now under local ... of the seas and coasts designed to protect wildlife ...
(Date:7/24/2014)... . , Electric cars ... common sight on the roads of the Scandinavian country ... new vehicle registrations for the second time. This poses a ... claim only a small portion of the market. Of the ... mere 8000 are electric powered. The main factors discouraging motorists ...
Breaking Biology News(10 mins):Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Western Indian Ocean communities play vital role in conservation 2Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3
... the National Human Genome Research Institute (NHGRI), part of ... has identified six more genetic variants involved in type ... genetic risk factors associated with increased risk of the ... new study had previously been suspected of playing a ...
... tiny gaps across which information crosses between nerve cells. ... play a vital role in both memory formation and ... Assistant professor Josh Dubnau, Ph.D., leads a ... fruit flies, or Drosophila. His team had previously identified ...
... shark populations worldwide are declining from destructive high-seas commercial ... products (mainly fins and meat), with some shark populations ... according to a comprehensive new book co-edited by shark ... www.pewoceanscience.org ), published by Blackwell Publishing, and being released ...
Cached Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists identify a mechanism that helps fruit flies lock-in memories 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 3Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 4
Request Info...
XBP-1 (F-4)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
pETDuet-1 is designed for the coexpression of two target genes....
Biology Products: